Chimeric antigen receptor

Show results for

Unknown (5405)
Genomics (744)
Transcriptomics (629)
Other (50)
Proteomics (38)
Clinical (27)
Models (14)
Metabolomics (7)
Methylation profiling (4)
Genomic (1)

Organisms

Homo sapiens (484)
Mus musculus (242)
Chlamydomonas reinhardtii (26)
Pseudomonas canadensis (26)
Arabidopsis thaliana (9)
Saccharomyces cerevisiae (5)
Bos taurus (3)
Mus sp. (2)
Acropora millepora (2)
Chlorocebus aethiops (2)
Rattus norvegicus (2)
Escherichia coli (2)
Mus musculus domesticus (2)
Canis lupus familiaris (2)
Streptomyces hygroscopicus subsp. jinggangensis (1)
Urocitellus parryii (1)
human gut metagenome (1)
Macaca nemestrina (1)
Escherichia coli O17 str. K12a (1)
Macaca mulatta (1)
Oryza sativa (1)
Rattus rattus (1)
Klebsiella pneumoniae (1)
Mycobacterium tuberculosis H37Rv (1)
Plasmodium falciparum (1)
Gallus gallus (1)
Sus scrofa (1)
Human immunodeficiency virus 1 (1)
synthetic construct (1)
Danio rerio (1)

Organisms

Homo sapiens (415)
Mus musculus (151)
Canis lupus familiaris (2)
Mus musculus domesticus (2)
Mus musculus musculus (1)
Human immunodeficiency virus 1 (1)
Danio rerio (1)
unidentified (1)

Repository

ENA (680)
geo (543)
biostudies-arrayexpress (190)
pride (26)
BioModels (14)
EGA (14)
MassIVE (11)
MetaboLights (7)
dbGaP (1)
jPOST (1)

Tissue

T cell (14)
Cell culture (7)
T-lymphocyte (2)
JURKAT cell (2)
Blood (2)
Neuroblastoma cell (1)
Ascites (1)
Macrophage (1)
Cell suspension culture (1)
Permanent cell line cell (1)
Epithelial cell (1)
B cell (1)
Liver (1)
Blood cell (1)

Disease

Colorectal Neoplasms (8)
Colorectal cancer (5)
Lymphoma (4)
Leukemia (3)
Acute leukemia (3)
Lymphoid leukemia (2)
Cancer (2)
Neuroblastoma (2)
Breast cancer (2)
Non-Hodgkin lymphoma (1)
Glioblastoma multiforme (1)
Advanced Hepatocellular Carcinoma (1)
Solid tumors mainly include but are not limited to advanced lung cancer, esophageal cancer and colorectal cancer (1)
Digestive tract tumors, including colorectal cancer, gastric cancer, pancreatic cancer, esophageal adenocarcinoma, esophagogastric junction cancer, etc (1)
Leukemia, Lymphoid (1)
Solid tumors (1)
Nasopharyngeal Carcinoma (1)
Glioma (1)
Neuroendocrine Tumors (1)
Carcinoma, Squamous Cell (1)
Melanoma (1)
Pancreatic Neoplasms (1)
Lung Cancer (1)
Adenocarcinoma (1)
Neoplasms (1)
Acute lymphocytic leukemia (1)
Alveolar rhabdomyosarcoma (1)
Rhabdomyosarcoma (1)
B-lymphoblastic leukemia/lymphoma (1)
B-cell acute lymphoblastic leukemia (1)

Technology Type

Mass Spectrometry (26)
Bottom-up proteomics (12)
Shotgun proteomics (8)
Mass spectrometry assay (4)
Data-dependent acquisition (4)
Affinity purification coupled with mass spectrometry proteomics (4)
Mass spectrometry (3)
Data-independent acquisition (2)
Illumina HiSeq 2000 (1)
Gel-based experiment (1)
Top-down proteomics (1)

Instrument Platform

NextSeq 500 (5)
Illumina NovaSeq 6000 (3)
Illumina HiSeq 2000 (3)
NextSeq 2000 (2)
Q Exactive (2)
Liquid Chromatography MS - negative - hydrophilic-interaction-liquid-chromatography (2)
Liquid Chromatography MS - negative - hilic (2)
Liquid Chromatography MS - positive - reverse phase (2)
Liquid Chromatography MS - negative - reverse phase (2)
GenePix 4000B [Axon Instruments] (1)
Illumina NovaSeq X (1)
MinION (1)
NextSeq 550 (1)
Illumina HiSeq 4000 (1)
Thermo Q-Exactive HF (QE) Quadrupole-Obitrap mass spectrometer (1)
Q-Exactive HF (QE) Quadrupole-Obitrap mass spectrometer (1)
QExactive HF (1)
LTQ Orbitrap Velos (1)
LTQ (1)
Orbitrap Eclipse (1)
Orbitrap Fusion (1)
TimsTOF Pro 2 (1)
Q Exactive HF (1)
Q Exactive Plus (1)
Orbitrap Fusion Lumos (1)
Liquid Chromatography MS - Negative (LC-MS (Negative)) (1)
GC-MS (1)
Liquid Chromatography MS - positive - hilic (1)

Publication Date

2025 (139)
2026 (137)
2024 (90)
2023 (87)
2021 (54)
2022 (46)
2015 (32)
2014 (25)
2011 (24)
2020 (23)
2018 (21)
2013 (20)
2012 (19)
2016 (16)
2010 (16)
2008 (13)
2019 (11)
2017 (6)
2009 (5)
2007 (4)
2005 (2)
2006 (1)

CHEBI ID

CHEBI:144829 (5)
CHEBI:17620 (2)
CHEBI:143591 (1)
CHEBI:143589 (1)
CHEBI:143588 (1)
CHEBI:143587 (1)
CHEBI:143584 (1)
CHEBI:144355 (1)
CHEBI:143583 (1)
CHEBI:143582 (1)
CHEBI:143580 (1)
CHEBI:144350 (1)
CHEBI:142657 (1)
CHEBI:143579 (1)
CHEBI:143578 (1)
CHEBI:91061 (1)
CHEBI:143581 (1)
CHEBI:143586 (1)
CHEBI:143592 (1)
CHEBI:87527 (1)
CHEBI:15040 (1)
CHEBI:144354 (1)
CHEBI:144356 (1)
CHEBI:174822 (1)
CHEBI:143585 (1)
CHEBI:73186 (1)
CHEBI:170015 (1)
CHEBI:165842 (1)
CHEBI:174200 (1)
CHEBI:139048 (1)

Metabolite Name

Methyl cis-15-tetracosenoate (1)
Cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester (1)
Methyl tetracosanoate (1)
Methyl tricosanoate (1)
Cis-13,16-Docosadienoic acid methyl ester (1)
Methyl erucate (1)
Methyl behenate (1)
Cis-11,14,17-Eicosatrienoic acid methyl ester (1)
Cis-11,14-Eicosadienoic acid methyl ester (1)
Cis-11-Eicosenoic acid methyl ester (1)
Methyl arachidate (1)
Methyl linoelaidate (1)
Methyl cis-10-heptadecenoate (1)
Methyl cis-10-pentadecenoate (1)
Methyl myristoleate (1)
Methyl tridecanoate (1)
Methyl undecanoate (1)
Methyl pentadecanoate (1)
Methyl gamma-linolenate (1)
Methyl octanoate (1)
Methyl heneicosanoate (1)
Methyl dodecanoate (1)
Methyl myristate (1)
Methyl heptadecanoate (1)
Cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester (1)
Rutin (1)
Methyl arachidonate (1)
Oleuropein (1)
Methyl stearate (1)
Methyl decanoate (1)

First Public Date

2026 (158)
2025 (146)
2024 (98)
2023 (87)
2022 (63)
2021 (58)
2020 (27)
2018 (23)
2019 (10)
2016 (3)
2015 (3)
2017 (2)
2014 (2)

Modelling Approach

Ordinary differential equation model (13)
Agent-based model (1)

Study status

Recruiting (13)
Not provided (6)
Not yet recruiting (5)
Suspended (1)
Withdrawn (1)
Completed (1)

Lab affiliation

Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA (2)
Moffitt Cancer Center (2)
Roswell Park Cancer Center Buffalo, NY, USA (2)
Department of Surgery Hollings Cancer Center (HO 512H) Medical University of South Carolina (1)
PRISM U1192, Universite de Lille France (Lab head) (1)
Assistant Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation (1)
Brown University MCB Department (1)
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center (1)
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland (1)
Laboratorio Core Facilities Gaslini Children's Hospital (1)
Department of Pharmaceutical Sciences, University at Buffalo, US (1)
Department of Biochemistry and Immunology, Ribeirão PretoMedical School, University of São Paulo, Ribeirão Preto, São Paulo, 14049-900, Brazil. (1)
Regeneron Pharmaceuticals, Tarrytown, NY (1)
Proteomics and Cancer Cell Signaling, DKFZ Heidelberg (lab head) (1)
1. Monash Proteomics and Metabolomics Facility, Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia 2. School of Clinical Sciences, Department of Medicine, Monash University, Clayton, Victoria, Australia (1)
Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, 02903 (1)
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), 138648 Singapore, Singapore. Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, 117543, Singapore, Singapore. (1)
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands (1)
Peter MacCallum Cancer Centre, 305 Grattan St Melbourne VIC 3000 (1)
Brown University, MCB Department (1)
UCSF (1)
Sylvester Comprehensive Cancer Center, Miami, FL, US. Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, US. (1)
Zhejiang University (1)

Keyword

CAR-T (3)
CEA (2)
Immunotherapy (2)
CAR-T cell (1)
Minimal residue disease (1)
NKG2D (1)
Gamma (1)
Delta (1)
CAR (1)
Chimeric antigen receptor (1)
Solid tumour (1)
Cancer immunotherapy (1)
Adoptive cell transfer (1)
CAR T cells (1)
CEA-positive advanced/metastatic solid tumors (1)
EpCAM (1)
Gene transfer (1)
Human Epidermal Growth Factor Receptor 2 (1)
Salivary Gland (1)
HER2 CAR-T (1)
Efficiency (1)
Refractory and relapsed cancer (1)
T cells (1)
Breast (1)
CAR T-cells (1)
Patient-Derived Organoids (1)
LGR5 (1)
T cell (1)
CAR T cell (1)
Safety (1)

IsPrivate

False (14)

Submitter Keywords

Immuno-oncology (8)

Classification

viruses (1)

Modification

4x(15)N labeled L-arginine (1)

Study type

Transcription profiling by array (112)
RNA-seq of coding RNA (25)
Interventional (23)
ChIP-seq (10)
ChIP-chip by tiling array (6)
Comparative genomic hybridization by array (6)
RNA-seq of non coding RNA (5)
Transcription profiling by RT-PCR (4)
Other (4)
RNA-seq of coding RNA from single cells (4)
Observational (4)
Unknown experiment type (3)
DNA-seq (2)
Methylation profiling by array (2)
Methylation profiling by high throughput sequencing (2)
Plant - Two-color microarray (1)
Genotyping by array (1)
ATAC-seq (1)
RIP-seq (1)
RNA-seq of total RNA (1)

Release Date

2023 (850)
2022 (802)
2021 (775)
2025 (750)
2024 (636)
2020 (502)
2019 (302)
2018 (242)
2017 (152)
2016 (103)
2026 (98)
2015 (98)
2014 (70)
2013 (52)
2011 (44)
2012 (38)
2010 (31)
2008 (16)
2009 (12)
2007 (10)
2005 (5)
2006 (3)
2004 (1)
2002 (1)
2000 (1)
1999 (1)

Location

China (19)
United States (3)
Norway (1)
Malaysia (1)
Belgium (1)
Australia (1)

Previous page
1 / 692
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 692
Next page

Sort by:

Relevance

Page size

A polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights

IFNγ-induced antigen loss in chimeric antigen receptor (CAR)-T cell therapy

PRJNA1431917 | ENA

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.

Not available

S-EPMC8863855 | biostudies-literature

Chimeric antigen receptor-microglia targeting glioblastoma within cortical organoid

PRJNA1251043 | ENA

Hardiansyah2019 - QSP model of chimeric antigen receptor T-Cell therapy

This QSP model explains how the mechanism of action connects to the clinical outcomes and, therefore, may serve as an important model-based platform to guide the development and personalized dosing of the CART therapy.

2025-01-15 | MODEL2009230001 | BioModels

NATCANCER-A16341B 1 2 iNV GOV 3 4GOV

Oncolytic viruses (OVs) are replication-competent viruses that selectively infect tumor cells and induce anti-tumor responses. However, systemic delivery is limited by neutralizing antibodies and poor intratumoral bioavailability. We developed iNV-GOV, a tumor-targeted, low-immunogenic platform that...

ORGANISM(S): Homo sapiens (Human)

2025-10-03 | PXD067837 | Pride

Inv gov and gov

Comparative analysis of T cell receptor and chimeric antigen receptor signaling in primary CD8+ T cells

Chimeric antigen receptor-modified (CAR) T cell therapy targeting highly expressed lineage antigens is effective for B cell malignancies. Achieving durable efficacy for hematological malignancies and extending this therapeutic approach to solid tumors will require T cell recognition and elimination ...

ORGANISM(S): Homo sapiens (Human)

2021-05-20 | PXD013734 | Pride

Chimeric antigen receptor T cell T cell receptor Immunotherapy Phosphoprotein signaling

chimeric antigen receptor T cells with knockout

PRJNA727540 | ENA

Epigenetic profiles of chimeric antigen receptor T cells with knockout of PRDM1

PRJNA726408 | ENA

Expression data from mouse CD19-targeted CAR (chimeric antigen receptor) T cells after antigen stimulation [RNA-seq]

PRJNA448192 | ENA

Previous page
1 / 692
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 692
Next page

Sort by:

Relevance

Page size

6919 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Classification

Modification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets